Veloxis Pharmaceuticals A/S announced that John Weinberg, M.D., currently chief commercial officer of Veloxis, has been promoted to chief operating officer. Dr. Weinberg, who is currently responsible for the commercial launch of Envarsus in the U.S., if approved by the Food and Drug Administration (FDA), will expand his role at the company to include additional operational responsibilities.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- DKK | -.--% | -.--% | -0.50% |
1st Jan change | Capi. | |
---|---|---|
-0.50% | 1.64B | |
+9.28% | 8.74B | |
-15.14% | 4.94B | |
+50.73% | 4.7B | |
+4.36% | 3.98B | |
-26.13% | 2.28B | |
+12.07% | 2.28B | |
+16.45% | 2.14B | |
-33.59% | 2.12B | |
-1.94% | 1.53B |
- Stock Market
- Equities
- VELO Stock
- News Veloxis Pharmaceuticals A/S
- Veloxis Pharmaceuticals A/S Promotes John Weinberg to Chief Operating Officer